Novel leukotriene A₄ hydrolase inhibitors

Abstract

Three applications from Searle claim closely related inhibitors of leukotriene A₄ (LTA₄) hydrolase, all of which are variations upon the structure of their existing lead compound SC-57641. These compounds are potent inhibitors of the isolated enzyme with significantly reduced activity in the presence of plasma proteins. They are of potential utility in the treatment of a number of inflammatory conditions.

• inflammatory bowel disease
• leukotriene B4 (LTB4)
• LTA4 hydrolase inhibitor